Stay updated with breaking news from Mark Velleca. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CAMBRIDGE, Mass. and NEW YORK, April 03, 2024 -- Black Diamond Therapeutics, Inc. , a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in...
Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for Q3 2024 in Phase 2 trial...
Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023...
Current Chairman of the Board and industry veteran Mark Velleca appointed CEO
19.12.2022 - CAMBRIDGE, Mass. and NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) - Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that Chairman ... Seite 1